Abiopharma

(50% Neutral) Allogene Therapeutics, Inc. (ALLO) Announces New Board Appointment

(75% Positive) Bicycle Therapeutics plc (BCYC) Provides Update on included for Bicycle’s wholly owned oncology pipeline

(10% Negative) Y-MABS THERAPEUTICS, INC. (YMAB) Announces Delay in included Trials for GD2-SADA New York Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(90% Positive) RedHill Biopharma (RDHL) Announces Clinical Development Update (Form 6-K)

(99% Neutral) SESEN BIO, INC. (SESN) Announces Clinical Development Update

(85% Positive) BELLUS Health Inc (the company became a subdivision of the company GSK (NYSE: GSK)) (BLU) Announces Clinical Development Update (Form 6-K)

(10% Negative) Leap Therapeutics, Inc. (LPTX) Announces Delay in disclosed Development Timeline Due to Manufacturing Considerations, Safety Review, Efficacy Assessment

(99% Neutral) TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Announces Regulatory Update

(99% Neutral) FULCRUM THERAPEUTICS, INC. (FULC) Announces Executive Departure

(93% Neutral) Genmab (GMAB) Announces Clinical Development Update (Form 6-K)